State-of-the-art facilities
Oxford, UK
Viral vector manufacturing in Oxford, UK
Benefit from:
6 GMP manufacturing suites
200L and 1,000L bioreactors
2 Fill Finish suites
17,030m2 (183,300ft2) total size of facilities
Greater Boston, US
Viral vector manufacturing in Greater Boston, US
Benefit from:
4 GMP manufacturing suites
500L, 1,000L, and 2,000L bioreactors
1 Fill Finish suite
8,920m 2 (96,000ft2) size of facility
Lyon, France
Viral vector manufacturing in Lyon, France
Benefit from:
3 GMP manufacturing suites
200L bioreactors
1 Fill Finish suite
2,570m2 (27,700ft2) size of facility
Strasbourg, France
Viral vector manufacturing in Strasbourg, France
Benefit from:
2 GMP manufacturing suites
500L bioreactors
1 Fill Finish suite
3,950m2 (42,500ft2) size of facility
Benefit from our deep scientific understanding
Working with Oxford Biomedica gives you access to capabilities that go far beyond conventional contract manufacturing services for viral vectors. Our commercial experience, scientific understanding, and development expertise complement our state of the art manufacturing facilities. Our teams are passionate about helping you get the results you want.
Benefit from our rigorous controls
When you use an Oxford Biomedica platform, you get a comprehensive, end-to-end CMC service. You can be sure our quality-focused GMP manufacturing processes will support your viral vector product through every step of development through to commercialisation, all supported by robust and compliant analytics.